A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. - Sternberg, C.N.; Saad, F.; Graff, J.N.; Peer, A.; Vaishampayan, U.N.; Leung, E.; Rosenbaum, E.; Gurney, H.; Epstein, R.J.; Davis, I.D.; Wu, B.; Trandafir, L.; et al. (Annals of Oncology, 2020)